Uncover key drivers, emerging technologies, and competitive movements shaping the rare biomarkers specimen collection and stabilization market from 2026–2035 with trusted insights from The Business Research Company
What level of CAGR-driven expansion is anticipated in the Rare Biomarkers Specimen Collection And Stabilization Market between 2026 and 2030?
The rare biomarkers specimen collection and stabilization market size has expanded quickly in recent years. This market is expected to grow from $35.29 billion in 2025 to $38.94 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.3%. The drivers behind this historical growth are an increase in molecular diagnostics research, the expansion of oncology biomarker studies, the availability of plasma-based testing methods, rising clinical trial activity, and a growing adoption of biobanking practices.
The rare biomarkers specimen collection and stabilization market is projected to experience substantial growth in the upcoming years, with its size anticipated to reach $55.35 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.2%. This expansion during the forecast period is primarily attributed to the increasing adoption of precision diagnostics, the rising demand for early disease detection, the broadening of genomic and transcriptomic testing, growing investments in biomarker-driven drug development, and the increasing integration of AI in biomarker analysis. Furthermore, key trends in this period will include the wider adoption of liquid biopsy collection techniques, the growing use of advanced stabilization reagents, a rising demand for high-sensitivity biomarker preservation, the expansion of non-invasive diagnostic applications, and an enhanced focus on sample integrity and traceability.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=15913&type=smp
What Drivers Are Affecting Demand-Supply Dynamics In The Rare Biomarkers Specimen Collection And Stabilization Market?
The projected rise in cancer cases is anticipated to boost the expansion of the rare biomarker specimen collection and stabilization market in the future. Cancer encompasses a wide range of illnesses marked by the uncontrolled multiplication and dispersion of atypical cells. This increase in cancer’s occurrence stems from various factors, including environmental exposures, lifestyle choices like smoking and unhealthy eating, and genetic predispositions, collectively fostering a greater demand for accurate diagnostic and surveillance instruments. The collection and stabilization of rare biomarker specimens are crucial for ensuring the precise preservation of biomarkers derived from blood and tissue, which are vital for early diagnosis, molecular characterization, and guiding treatment choices in cancer care. As an illustration, in February 2024, the World Health Organization, an intergovernmental body based in Switzerland, predicted that by 2050, there would be more than 35 million new cancer diagnoses, indicating a 77% rise from the approximately 20 million cases estimated in 2022. Consequently, the growing incidence of cancer is fueling the expansion of the rare biomarker specimen collection and stabilization market.
What Segments Are Included Within The Rare Biomarkers Specimen Collection And Stabilization Market?
The rare biomarkers specimen collection and stabilization market covered in this report is segmented –
1) By Type: Circulating Cell Free Deoxyribonucleic Acid (CCFDNA), Circulating Tumor Cells (CTCs), Exosomes or Extracellular Vesicles
2) By Specimen: Serum Or Plasma, Other Specimens
3) By Application: Non-Invasive Prenatal Testing (NIPT), Oncology, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Cardiovascular Diseases, Other Applications
4) By End-User: Hospitals, Perinatal Clinics, Public Health Labs, Private Or Commercial Labs, Physician Labs, Research Institutes, Other End-Users
Subsegments:
1) By Circulating Cell Free Deoxyribonucleic Acid (CCFDNA): Plasma CCFDNA, Serum CCFDNA
2) By Circulating Tumor Cells (CTCs): CTCs In Blood, CTCs In Bone Marrow
3) By Exosomes Or Extracellular Vesicles: Exosomes From Plasma, Exosomes From Serum
Which Trends Are Influencing The Development Of The Rare Biomarkers Specimen Collection And Stabilization Market?
Leading companies within the rare biomarkers specimen collection and stabilization market are concentrating on developing advanced solutions, such as automated plasma and cell sample preparation, to safeguard biomarker integrity and enable high-throughput multiomics analysis. Automated pre-analytical platforms represent technologies designed to standardize blood sample processing, encompassing steps like plasma separation, cell fixation, and slide preparation directly at the point of collection, thereby ensuring consistent specimen quality without manual handling or specialized tubes. For example, in April 2024, Tethis S.p.A., an Italy-based biotechnology company, announced the enrollment of its first two patients in a clinical study for its See.d platform. This platform automates the standardized preparation of plasma and cell samples for multiomic liquid biopsy, which includes the fixation of rare circulating tumor and immune cells onto nanocoated SmartBioSurface slides. Designed to maximize sample integrity and enable seamless analysis of cell-free DNA and circulating tumor cells from a single draw, the platform supports the entire workflow of rare biomarker specimen collection and stabilization.
Who Are The Primary Competitors In The Global Rare Biomarkers Specimen Collection And Stabilization Market?
Major companies operating in the rare biomarkers specimen collection and stabilization market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Becton Dickinson and Company, Eurofins Scientific SE, Agilent Technologies Inc., PerkinElmer Inc., Illumina Inc., Charles River Laboratories International Inc., Bio-Rad Laboratories Inc., Bruker Corporation, QIAGEN N.V., Miltenyi Biotec GmbH, Natera Inc., Promega Corporation, Myriad Genetics, Hamilton Company, OraSure Technologies Inc., Fluidigm Corporation, Streck Inc., SeraCare, Enzo Biochem Inc., Epigenomics AG, Veridex LLC
Access The Complete Report For Deeper Market Insights:
Which Global Regions Are Shaping The Competitive Landscape Of The Rare Biomarkers Specimen Collection And Stabilization Market?
North America was the largest region in the rare biomarkers specimen collection and stabilization market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the rare biomarkers specimen collection and stabilization market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Rare Biomarkers Specimen Collection And Stabilization Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=15913&type=smp
Browse Through More Reports Similar to the Global Rare Biomarkers Specimen Collection And Stabilization Market 2026, By The Business Research Company
Biomarker Discovery Outsourcing Services Market Report 2026
Clinical Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report
Biomarkers Market Report 2026
https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model